We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · March 20, 2021

Cetuximab, Docetaxel, and Cisplatin vs Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Recurrent or Metastatic HNSCC

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Cetuximab, Docetaxel, and Cisplatin Versus Platinum, Fluorouracil, and Cetuximab as First-Line Treatment in Patients With Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma (GORTEC 2014-01 TPExtreme): A Multicentre, Open-Label, Randomised, Phase 2 Trial
Lancet Oncol 2021 Mar 05;[EPub Ahead of Print], J Guigay, A Aupérin, J Fayette, et al

Further Reading